DoH policies Equality Screened 1 April to 30 June 2015
Date published:
In fulfilling its commitments within its Equality Scheme the Department equality screens policies to assess the impact and determine if a full Equality Impact Assessment (EQIA) is required
Documents
- Amendments to Controlled Drugs Regulations Northern Ireland 2009
- A Safeguarding Policy for Children and Young People in Northern Ireland
- NICE Clinical Guideline CG61 Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care – Addendum
- NICE Guidelines NG3 - Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period - This guideline updates and replaces NICE guideline CG63
- NICE (Clinical) Guidelines NG5 - Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes
- NICE Guidance NG6 - Excess winter deaths and morbidity and the health risks associated with cold homes
- NICE (Public Health) Guidelines NG7 - Maintaining a healthy weight and preventing excess weight gain among adults and children
- NICE Guidance PH49 - Behaviour change: individual approaches
- NICE Technology Appraisal TA330 - Sofosbuvir for treating chronic hepatitis C
- NICE Technology Appraisal TA 335 - Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
- NICE Technology Appraisal TA 336 - Empagliflozin in combination therapy for treating type 2 diabetes
- NICE Technology Appraisal TA 337 - Rifaximin for maintaining remission from episodes of hepatic encephalopathy
- NICE Technology Appraisal TA 338 - Pomalidomide for treating relapsed and refractory multiple myeloma previously treated with both lenalidomide and bortezomib
- NICE Technology Appraisal TA339 - Omalizumab for treating previously treated chronic spontaneous urticaria
- NICE Technology Appraisal TA340 - Ustekinumab for treating active psoriatic arthritis (Rapid Review of TA313)
- NICE Technology Appraisal TA 341 - Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
- NICE Technology Appraisal TA342 - Vedolizumab for treating moderately to severely active ulcerative colitis
- NICE Technology Appraisal TA343 - Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
- NICE Technology Appraisal TA344 - Ofatumumab in combination with chlorambucil or bendamustine for previously untreated chronic lymphocytic leukaemia
- Service Framework for Respiratory Health and Wellbeing